Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
|Articles|August 29, 2012
Even With the New Deadline, 'Time is Running Out' on ICD-10
Advertisement
CD-10
Now that the Department of Health and Human Services has decided on the new
That doesn't leave a lot of time for healthcare organizations to meet the mandate, particularly those who have not yet even started the conversion. Deb Grider, senior manager of Blue & Co. consultancy, talks about how she sees the new deadline being perceived in healthcare, discusses the reality of some health entities still being in denial that ICD-10 will happen and suggests how those already into the transition can adjust their plans to make use of the extra year.
Read the full story:
Source: Healthcare Payer News
Advertisement
Related to this article
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5